Lista de obras - Peter Barrett-Lee - Dominio Público Uruguay

3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response

artículo científico publicado en 2016

A patient with breast cancer and paraneoplastic cerebellar syndrome associated with anti-Purkinje cell antibodies: Response to CMF chemotherapy ⬇️

artículo científico publicado el 1 de enero de 1998

A prognostic tool to predict fatigue in women with early-stage breast cancer undergoing radiotherapy.

artículo científico publicado en 2012

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

artículo científico publicado en 2015

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

artículo científico

Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells

artículo científico publicado en 2008

Aromatase inhibitors in breast cancer

artículo científico publicado en 2009

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.

artículo científico publicado en 2014

Breast cancer follow-up: a radiographer-led service.

artículo científico publicado en 2004

Breast-cancer adjuvant therapy with zoledronic acid ⬇️

artículo científico publicado en 2011

Cardiotoxicity and anthracyclines

artículo científico publicado en 2008

Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

artículo científico publicado en 2005

Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.

artículo científico publicado en 2005

Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.

artículo científico publicado en 2005

Duration of adjuvant chemotherapy; anthracyclines, taxanes and novel agents--more or less.

artículo científico publicado en 2002

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer ⬇️

artículo científico publicado en 2012

Effect of patient age on management decisions in breast cancer: consensus from a national consultation.

artículo científico publicado en 2010

Epoetin Alfa Improves Anemia and Anemia-Related, Patient-Reported Outcomes in Patients with Breast Cancer Receiving Myelotoxic Chemotherapy: Results of a European, Multicenter, Randomized, Controlled Trial ⬇️

artículo científico publicado el 26 de agosto de 2010

Experiences of men with breast cancer: an exploratory focus group study.

artículo científico publicado en 2003

Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?

artículo científico publicado en 2011

Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial

artículo científico publicado en 2015

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).

artículo científico publicado en 2011

Genetic Testing Considerations in Breast Cancer Patients.

artículo científico publicado en 1999

Growth factor expression in Breast tissue

article

HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales.

artículo científico publicado en 2010

How do patients want to learn of results of clinical trials? A survey of 1431 breast cancer patients.

artículo científico publicado en 2007

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy

artículo científico publicado en 2007

Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network

artículo científico publicado en 2014

Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.

artículo científico publicado en 2010

Iron and the anaemia of chronic disease: a review and strategic recommendations.

artículo científico publicado en 2006

Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy

artículo científico publicado en 2000

Male cancer: a qualitative study of male breast cancer.

artículo científico publicado en 2000

Mammographic follow-up of patients after treatment for breast cancer: is 5 years enough?

artículo científico publicado en 2010

Mesenchymal chondrosarcoma of the maxilla

artículo científico publicado en 1994

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.

artículo científico publicado en 2013

Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.

artículo científico publicado en 2012

Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer

artículo científico

Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate?

article

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

artículo científico publicado en 2013

Pro-metastatic tumor-stroma interactions in breast cancer.

artículo científico publicado en 2012

Psychological and immunological characteristics of fatigued women undergoing radiotherapy for early-stage breast cancer

artículo científico publicado en 2012

QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.

artículo científico publicado en 2013

Radiotherapy for skin cancer: as good as surgery?

artículo científico publicado en 2014

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer ⬇️

artículo científico publicado el 11 de marzo de 2011

Senior Registrars' training: Time for research

scientific article published on 01 January 1994

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

artículo científico publicado en 2009

Soluble interleukin-6 receptor mediated fatigue highlights immunological heterogeneity of patients with early breast cancer who undergo radiation therapy

article

Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention ⬇️

artículo científico publicado el 1 de mayo de 2011

Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer

artículo científico publicado en 2005

TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC.

artículo científico publicado en 2006

Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response ⬇️

artículo científico publicado el 28 de agosto de 2013

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

artículo científico publicado en 2004

The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.

artículo científico publicado en 2008

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

artículo científico publicado en 2013

The use of randomisation-based efficacy estimators in non-inferiority trials.

artículo científico publicado en 2015

Trastuzumab in Patients on Haemodialysis for Renal Failure

scientific article published on 12 June 2007

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study

artículo científico publicado en 2013

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

artículo científico publicado en 2005

γδ T cells predict outcome in zoledronate-treated breast cancer patients.

artículo científico publicado en 2013

Lista de obras de Peter Barrett-Lee

3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response

A patient with breast cancer and paraneoplastic cerebellar syndrome associated with anti-Purkinje cell antibodies: Response to CMF chemotherapy ⬇️

A prognostic tool to predict fatigue in women with early-stage breast cancer undergoing radiotherapy.

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial

Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells

Aromatase inhibitors in breast cancer

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.

Breast cancer follow-up: a radiographer-led service.

Breast-cancer adjuvant therapy with zoledronic acid ⬇️

Cardiotoxicity and anthracyclines

Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.

Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.

Duration of adjuvant chemotherapy; anthracyclines, taxanes and novel agents--more or less.

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer ⬇️

Effect of patient age on management decisions in breast cancer: consensus from a national consultation.

Epoetin Alfa Improves Anemia and Anemia-Related, Patient-Reported Outcomes in Patients with Breast Cancer Receiving Myelotoxic Chemotherapy: Results of a European, Multicenter, Randomized, Controlled Trial ⬇️

Experiences of men with breast cancer: an exploratory focus group study.

Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?

Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial

First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015).

Genetic Testing Considerations in Breast Cancer Patients.

Growth factor expression in Breast tissue

HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales.

How do patients want to learn of results of clinical trials? A survey of 1431 breast cancer patients.

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy

Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network

Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.

Iron and the anaemia of chronic disease: a review and strategic recommendations.

Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy

Male cancer: a qualitative study of male breast cancer.

Mammographic follow-up of patients after treatment for breast cancer: is 5 years enough?

Mesenchymal chondrosarcoma of the maxilla

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.

Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.

Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer

Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate?

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

Pro-metastatic tumor-stroma interactions in breast cancer.

Psychological and immunological characteristics of fatigued women undergoing radiotherapy for early-stage breast cancer

QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.

Radiotherapy for skin cancer: as good as surgery?

Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer ⬇️

Senior Registrars' training: Time for research

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

Soluble interleukin-6 receptor mediated fatigue highlights immunological heterogeneity of patients with early breast cancer who undergo radiation therapy

Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention ⬇️

Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer

TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC.

Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response ⬇️

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

The use of randomisation-based efficacy estimators in non-inferiority trials.

Trastuzumab in Patients on Haemodialysis for Renal Failure

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study

Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration

γδ T cells predict outcome in zoledronate-treated breast cancer patients.